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Objective. Rheumatoid arthritis (RA) is associ-
ated with an increased risk of coronary artery disease,
possibly acting via shared mechanisms of inflammation.
This study was undertaken to test the hypothesis that
the powerful antiinflammatory effect of anti–tumor
necrosis  (anti-TNF) therapy might lead to a reduc-
tion in the incidence of myocardial infarction (MI) in
patients with RA.
Methods. Using data from the British Society for
Rheumatology Biologics Register, a national prospective
observational study, we compared MI rates in 8,670
patients with RA treated with anti-TNF and 2,170
patients with active RA treated with traditional disease-
modifying antirheumatic drugs (DMARDs).
Results. Through July 2006, 63 MIs occurred in
the anti-TNF cohort during 13,233 person-years of
followup and 17 MIs occurred in the DMARD cohort
during 2,893 person-years of followup, equivalent to a
rate of 4.8 events per 1,000 person-years and 5.9 events
per 1,000 person-years, respectively. After adjustment
for baseline risk factors, there was no reduction in the
rate of MI in the anti-TNF cohort compared with the
DMARD cohort (incidence rate ratio 1.44 [95% confi-
dence interval 0.56–3.67]). In an analysis of anti-TNF–
treated patients who responded to the treatment within
6 months versus those who did not, MI rates were found
to be 3.5 events per 1,000 person-years in responders
and 9.4 events per 1,000 person-years in nonresponders.
The adjusted incidence rate ratio (95% confidence in-
terval) for responders compared with nonresponders
was 0.36 (0.19–0.69).
Conclusion. These results indicate that RA pa-
tients treated with anti-TNF do not have a lower
incidence of MI compared with RA patients treated with
traditional DMARDs. However, the risk of MI is mark-
edly reduced in those who respond to anti-TNF ther-
apy by 6 months compared with nonresponders. This
finding supports the notion that inflammation plays a
pivotal role in MI.
It is now well established that rheumatoid arthri-
tis (RA) is associated with increased mortality and
morbidity due to accelerated atherosclerosis, including
from myocardial infarction (MI) (1–5). This increased
risk cannot be attributed to traditional cardiovascular
risk factors, such as smoking and hypertension, alone
(2,5,6). There is mounting evidence that the increased
risk is related to the overall burden of inflammatory
disease in RA (7,8). In addition, atherosclerosis itself
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2905is increasingly being viewed as an inflammatory condi-
tion (9).
The cytokine tumor necrosis factor  (TNF)
plays a key role in the pathogenesis of RA (10). Intro-
duction of the anti-TNF therapies infliximab, etaner-
cept, and adalimumab has dramatically improved the
outcome of severe RA beyond that achieved with tradi-
tional disease-modifying antirheumatic drugs
(DMARDs) (11–13). Proinflammatory cytokines, in-
cluding TNF, are involved in modification of lipid
profile and insulin resistance (14) and the initiation and
progression of atherosclerosis (15,16), hemostasis (17),
and atherosclerotic plaque rupture, the most common
event leading to an acute MI (15). Inhibition of TNF in
patients with RA may therefore lead to a reduction in
MI rates by inhibiting one or more of these mechanisms.
However, some patients do not respond well to anti-
TNF drugs. Therefore, we hypothesized that any re-
duction in the incidence of MI would be limited to those
patients who displayed a good clinical response to TNF.
The aims of this study were, first, to determine
whether the incidence of MI in RA patients treated with
anti-TNF was lower than that in patients treated with
traditional DMARDs and, second, to explore the impact
of response to treatment on the rates of MI in the
anti-TNF cohort. To date, 1 study has shown a reduced
rate of all cardiovascular events following anti-TNF
therapy (18), but no published studies have so far
explored MI incidence or the influence of treatment
response.
PATIENTS AND METHODS
Patients. Subjects were participants in a large national
prospective observational study, the British Society for Rheu-
matology Biologics Register (BSRBR). Methods of patient
recruitment and followup have been described in detail else-
where (19). Briefly, the study aims to recruit all UK patients
with rheumatic diseases treated with biologic agents, and an
appropriate comparison group, in order to examine the long-
term safety of these drugs. UK national guidelines recommend
that anti-TNF drugs be reserved for patients with active RA,
defined as a Disease Activity Score in 28 joints (DAS28) (20)
5.1 despite previous therapy with at least 2 DMARDs, one of
which should be methotrexate (21), and that “any clinician
prescribing these medications must (with the patient’s permis-
sion) undertake to register the patient with the [BSRBR] and
forward information on dosage, outcome and toxicity on a
six-monthly basis” (22).
Anti-TNF cohort. This cohort was restricted to pa-
tients registered with the BSRBR who were diagnosed as
having RA and were treated with an anti-TNF drug. Patients
who were registered with the BSRBR 6 months after the
start of biologic therapy were excluded. Patients had to have
been followed up for 6 months by July 31, 2006.
Comparison cohort. A cohort of patients with active
RA who have never taken biologic agents is being recruited in
parallel with the anti-TNF cohort by the BSRBR Control
Centre Consortium (see Appendix A for a list of BSRBR
Control Centre Consortium members). The comparison co-
hort is followed up using the same methodology used to follow
up the anti-TNF cohort (19). The patients in the comparison
cohort were diagnosed as having active RA (guideline
DAS28 4.2) despite current treatment with a traditional
DMARD. These patients also had to have been followed up
for 6 months by July 31, 2006.
Baseline assessment. Baseline data assessed in both
cohorts included demographic characteristics, disease dura-
tion, 28-joint counts for swelling and tenderness, erythrocyte
sedimentation rate and/or C-reactive protein level, and patient
global assessment, and enabled calculation of a DAS28 score
(20). Details of all previous and current DMARD therapy and
all other current medications were obtained. Patients com-
pleted a Health Assessment Questionnaire (HAQ) adapted for
British use (23). Townsend scores of multiple deprivation were
calculated based on the patient’s area of residence and com-
pared with UK quintiles (24). Data were also collected on
other variables that might influence cardiovascular risk, includ-
ing all baseline drugs, body mass index (BMI), prior cardio-
vascular comorbidity (including previous MI, angina, and
hypertension), diabetes, and smoking history.
Followup. Data on changes in therapy, disease activity,
and the occurrence of adverse events were collected in 3 ways.
Rheumatologists were sent a questionnaire every 6 months,
patients were sent a 6-month diary in which to document all
hospital admissions, new medications, and new hospital refer-
rals, and all patients were flagged with the UK General
Register Office, which provides the BSRBR with information
on deaths and cause of death (coded according to the Inter-
national Statistical Classification of Diseases and Related
Health Problems, Tenth Revision) (25). If an MI was reported
from any of the 3 sources, further supporting information, such
as a hospital discharge summary, was requested from the
rheumatologist.
All available clinical information on the MIs was
reviewed by 2 physicians (WGD and KLH) independently to
verify the diagnosis according to an adapted European Society
of Cardiology (ESC)/American College of Cardiology (ACC)
definition (26). ESC/ACC criteria define an acute, evolving, or
recent MI as a typical rise and fall of biochemical markers of
myocardial necrosis with 1 of the following: ischemic symp-
toms, Q waves, ischemic electrocardiography changes, coro-
nary artery intervention, or pathologic findings of an acute MI.
Additional BSRBR verification criteria were thrombolysis
and/or MI recorded on death certificate, regardless of autopsy
confirmation. Any disagreement was resolved by consensus
following discussion. Only verified MIs were included in the
analysis.
Statistical analysis. Response to treatment in the
anti-TNF cohort was defined according to European League
Against Rheumatism criteria (27). Responders were those
patients who achieved either a good or a moderate response,
i.e., a reduction in the DAS28 score from baseline to 6 months
of 1.2, or a reduction of 0.6 in addition to a DAS28 score
of 5.1 at 6 months. DAS28 scores were not measured at 6
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assessed in this group.
For patients in the anti-TNF cohort, person-years of
followup included only the time during which they were
actively treated with the first anti-TNF drug. The date of drug
discontinuation was defined as the date of the first missed
dose. Person-years were calculated from the first day of
anti-TNF therapy to the date of the most recent completed
followup form prior to July 31, 2006, drug discontinuation, first
MI, or death, whichever came first. Thus, only the first MI for
an individual patient was analyzed. For the purposes of the
current analysis, only MIs occurring while the patient was
undergoing active treatment were attributable to that drug. If
an MI occurred after a patient discontinued the first anti-
TNF agent, that event was not included in the analysis,
regardless of whether the patient had been started on a new
anti-TNF drug.
For patients in the comparison cohort, person-years of
followup included the time from the date of registration until
the date of the most recent completed followup form prior to
July 31, 2006, first MI, or death, whichever came first. For
patients initially registered in the comparison cohort who
subsequently received an anti-TNF drug, person-years of
followup in the comparison cohort included the time up to the
date the anti-TNF drug was started, and person-years of
followup in the anti-TNF cohort included the subsequent
time, during which they were actively treated with the anti-
TNF drug.
Incidence rates of MI are presented as events per
1,000 person-years, with 95% confidence intervals (95% CIs).
Incidence rate ratios were calculated using Poisson regression,
initially comparing the anti-TNF cohort with the DMARD
cohort, and then comparing responders with nonresponders
within the anti-TNF cohort. Stepwise adjustment was per-
formed, first for age and sex, and then additionally for RA
disease severity (using baseline DAS28 score, HAQ, and
disease duration as continuous variables), BMI, social depri-
vation (Townsend quintiles), cardiovascular comorbidity (pre-
vious MI, angina, hypertension), diabetes, smoking status
(current, ever, or never), and baseline use of selected drugs
Table 1. Baseline characteristics of the DMARD-treated and anti-TNF–treated patients*
Characteristic
DMARD
(n  2,170)
All anti-TNF
(n  8,659)
Anti-TNF
nonresponders
(n  1,638)
Anti-TNF
responders
(n  5,877) P†
Age, mean  SD years 60  12 56  12‡ 57  12 56  12 0.002
Sex, % female 72 76‡ 79 76 0.01
DAS28 score, mean  SD 5.0  1.4 6.6  1.0‡ 6.4  1.1 6.6  1.0 0.001
HAQ score, mean  SD 1.5  0.8 2.1  0.6‡ 2.2  0.5 2.0  0.6 0.001
Disease duration, median (IQR) years 7 (1–15) 12 (6–19)‡ 11 (6–19) 11 (6–19) 0.64
BMI, mean  SD kg/m
2 26.9  5.7 26.7  5.8§ 26.9  6.2 26.7  5.7 0.27
Smoking history, no. (%)¶ 0.07#
Current smoker 537 (25) 1,886 (22) 382 (23) 1,231 (21)
Former smoker 849 (39) 3,298 (38) 625 (38) 2,241 (38)
Never smoked 767 (35) 3,431 (40) 621 (38) 2,369 (40)
Prior MI, no. (%) 116 (5.3) 250 (2.9)‡ 48 (2.9) 154 (2.6) 0.48
Angina, no. (%) 183 (8.4) 381 (4.4)‡ 85 (5.2) 240 (4.1) 0.04
Hypertension, no. (%) 672 (31.0) 2,581 (29.8) 506 (30.9) 1,731 (29.4) 0.19
Diabetes, no. (%) 132 (6.1) 470 (5.4) 110 (6.7) 287 (4.9) 0.003
Corticosteroids, no. (%) 418 (19.3) 3,793 (43.7)‡ 743 (45.3) 2,519 (42.9) 0.06
Lipid-lowering drugs, no. (%) 338 (15.6) 768 (8.9)‡ 159 (9.7) 502 (8.5) 0.14
Antiplatelet drugs, no. (%) 291 (13.4) 648 (7.5)‡ 130 (7.9) 418 (7.1) 0.26
NSAIDs, no. (%) 1,344 (61.9) 5,705 (65.9)** 995 (60.8) 3,961 (67.4) 0.001
Townsend quintile, no. (%)¶†† 0.001#
1 314 (14.5) 1,388 (16.0) 260 (15.9) 973 (16.6)
2 301 (13.9) 1,469 (17.0) 250 (15.3) 1,021 (17.4)
3 382 (17.6) 1,633 (18.9) 279 (17.0) 1,154 (19.6)
4 443 (20.4) 1,881 (21.7) 380 (23.2) 1,263 (21.5)
5 655 (30.2) 1,933 (22.3) 402 (24.6) 1,217 (20.7)
* The number of anti–tumor necrosis factor  (anti-TNF) responders and the number of anti-TNF nonresponders do not equal the total number
of anti-TNF–treated patients, since information on the change in Disease Activity Score in 28 joints (DAS28) from 0 to 6 months was not available
in 1,153 patients. For smoking history, prior myocardial infarction (MI), angina, hypertension, diabetes, corticosteroids, lipid-lowering drugs,
antiplatelet drugs, nonsteroidal antiinflammatory drugs (NSAIDs), and Townsend quintiles, data were not available in all patients. HAQ  Health
Assessment Questionnaire; IQR  interquartile range; BMI  body mass index.
† Anti-TNF nonresponders versus anti-TNF responders.
‡ P  0.001 versus disease-modifying antirheumatic drug (DMARD)–treated patients.
§ P  0.04 versus DMARD-treated patients.
¶ P for trend  0.001.
# P for trend.
** P  0.001 versus DMARD-treated patients.
†† Quintile 1 represents the least socially deprived; quintile 5 represents the most socially deprived.
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lowering drugs, and antiplatelet drugs). All analyses were
performed using Stata, version 8.2 software (StataCorp, Col-
lege Station, TX).
RESULTS
A total of 10,755 patients were included in the
analysis: 8,659 in the anti-TNF cohort (3,844 receiving
etanercept, 2,944 receiving infliximab, and 1,871 receiv-
ing adalimumab) and 2,170 in the comparison cohort.
Seventy-four patients switched from the comparison
cohort to the anti-TNF cohort and were included in
both cohorts. Baseline characteristics are shown in
Table 1. The comparison cohort included proportionally
more men, and patients in this cohort were older than
those in the anti-TNF group. As anticipated, patients
in the comparison cohort had less severe disease of
shorter duration and had a lower rate of steroid use at
baseline. There were significantly higher rates of previ-
ous MI and angina in the DMARD cohort, and signifi-
cantly higher rates of use of lipid-lowering and antiplate-
let drugs. Proportionally more patients in the DMARD
cohort were in the most socially deprived quintile. As
mentioned above, these differences were adjusted for in
subsequent analyses.
The median followup was 1.66 years in the anti-
TNF cohort and 1.34 years in the DMARD cohort.
There were 69 reported MIs in the anti-TNF cohort
compared with 20 in the comparison cohort. Of these, 63
and 17, respectively, were verified (Table 2). The crude
incidence rate of MI was lower in the anti-TNF cohort
(4.8 events per 1,000 person-years) than in the DMARD
cohort (5.9 events per 1,000 person-years), equivalent to
an incidence rate ratio (95% CI) of 0.81 (0.47–1.38).
However, after adjustment for age and sex, the incidence
rate ratio increased to 1.13, and further adjustment for
RA disease severity, social deprivation, traditional car-
diovascular risk factors, and relevant baseline drug use
resulted in an incidence rate ratio (95% CI) of 1.44
(0.56–3.67). Inclusion of the nonverified MIs in the
analysis resulted in an adjusted incidence rate ratio
Table 3. Incidence rates of verified first MI in nonresponders and responders to anti-TNF treatment*
Nonresponders
(n  1,638)
Responders
(n  5,877)
Person-years 1,815 9,886
No. of reported MIs 17 35
Rate of MIs per 1,000 person-years (95% CI) 9.4 (5.5–15.0) 3.5 (2.5–4.9)
Incidence rate ratio Referent 0.38 (0.21–0.67)
Incidence rate ratio, adjusted for age and sex Referent 0.38 (0.22–0.68)
Incidence rate ratio, multivariate analysis† Referent 0.36 (0.19–0.69)
Incidence rate ratio by sex, multivariate analysis†
Male patients Referent 0.31 (0.12–0.81)
Female patients Referent 0.46 (0.20–1.06)
* 95% CI  95% confidence interval (see Table 1 for other definitions).
† Adjusted for age, sex, disease severity, body mass index, social deprivation, smoking history, comorbid-
ity, and baseline drug use.
Table 2. Incidence rates of verified first MI in DMARD-treated and anti-TNF–treated patients*
All patients Male patients Female patients
DMARD
(n  2,170)
Anti-TNF
(n  8,659)
DMARD
(n  615)
Anti-TNF
(n  2,072)
DMARD
(n  1,555)
Anti-TNF
(n  6,587)
Person-years 2,893 13,233 831 3,199 2,062 10,034
No. of reported MIs 17 63 10 27 7 36
Rate of MIs per 1,000
person-years (95% CI)
5.9 (3.4–9.4) 4.8 (3.7–6.1) 12.0 (5.8–22.1) 8.4 (5.5–12.2) 3.4 (1.4–7.0) 3.6 (2.5–5.0)
Incidence rate ratio Referent 0.81 (0.47–1.38) Referent 0.70 (0.34–1.45) Referent 1.06 (0.47–2.37)
Incidence rate ratio,
adjusted for age and sex
Referent 1.13 (0.65–1.96) Referent 0.92 (0.43–0.98) Referent 1.39 (0.62–3.14)
Incidence rate ratio,
multivariate analysis†
Referent 1.44 (0.56–3.67) Referent 0.96 (0.26–3.55) Referent 2.07 (0.62–6.88)
* 95% CI  95% confidence interval (see Table 1 for other definitions).
† Adjusted for age, sex, disease severity, body mass index, social deprivation, smoking history, comorbidity, and baseline drug use.
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to patients who had no prior MI or angina, the adjusted
incidence rate ratio (95% CI) for verified MIs was
largely unchanged at 1.38 (0.46–4.18). Rates of MI were
higher in men, as expected, in both cohorts. There was
again no significant difference in risk of MI with anti-
TNF therapy for either sex.
Information on change in DAS28 score from 0 to
6 months was not available for 1,144 of the anti-TNF–
treated patients. In the remaining 7,515 patients, the
incidence of MI in responders to anti-TNF treatment
was 3.5 events per 1,000 person-years, compared with
9.4 events per 1,000 person-years in nonresponders,
with an adjusted incidence rate ratio (95% CI) of 0.36
(0.19–0.69) (Table 3). This effect was slightly stronger
in men (adjusted incidence rate ratio 0.31 for men and
0.46 for women). Inclusion of the nonverified MIs
resulted in an adjusted incidence rate ratio (95% CI) of
0.43 (0.23–0.80).
Followup rates in the BSRBR were excellent.
Only 2.2% of all patients who were registered 12
months prior to July 31, 2006 had no returned rheuma-
tologist questionnaires and 17.2% had no returned
patient diaries. Only 0.6% had no followup information
from either source. Patients with no returned followup
information from the rheumatologist were not included
in this analysis.
DISCUSSION
We have shown that there is no overall reduction
in MI rate in the short term in anti-TNF–treated RA
patients, compared with DMARD-treated patients with
active RA who had never taken biologic agents. How-
ever, in RA patients who responded to anti-TNF
therapy, the risk of MI was reduced by more than half
compared with nonresponders. This is consistent with
the hypothesis that suppression of inflammation may
reduce cardiovascular risk. Because we did not measure
DAS28 scores in the DMARD cohort at 6 months, we
cannot determine whether reduction in RA disease
activity secondary to any treatment is associated with a
reduction in MI incidence, or whether this finding is
specific to anti-TNF therapy.
This early reduction in MI risk in responders
cannot be extrapolated to indicate a long-term beneficial
cardiac effect. Raised levels of TNF in chronic heart
failure (28), along with the predictive value of high levels
of TNF on adverse outcome in chronic heart failure
(29), led to studies to explore the potential benefit of
anti-TNF therapy in severe chronic heart failure. Con-
trary to expectations, 2 studies of etanercept had to be
terminated early when interim analysis showed a lack of
efficacy (30), and high-dose infliximab was shown to be
detrimental in patients with moderate to severe chronic
heart failure (31).
After MI, TNF inhibition may potentially have
both harmful and beneficial effects on myocardial func-
tion. TNF has a protective role in the physiologic
adaptive response to injury and limits infarct size (32),
although when overexpressed it can lead to maladaptive
effects, such as promoting left ventricular dysfunction
(33). Evidence of the effect of anti-TNF therapy on
heart failure in RA patients without preexisting heart
failure is currently very limited.
Despite the pleiotropic effects of TNF inhibi-
tion on the heart, the focus of the current investigation
was solely on MI rates during this early period of
exposure. Given the link between plaque inflammation
and plaque rupture (34), it is plausible that there might
be an early reduction in MI incidence following anti-
TNF treatment, while potential effects on heart failure,
if any, may only be noticeable over a longer time period.
There are important methodologic issues which
must be considered when interpreting these data. The
BSRBR is an observational study aimed at nationwide
ascertainment of data related to anti-TNF treatment,
using an appropriate comparison group. As anticipated,
patients in the anti-TNF cohort had more severe
disease. This difference should, if anything, have placed
the anti-TNF cohort at increased risk of MI. Con-
versely, the comparison cohort had higher rates of
baseline cardiovascular risk factors, with greater base-
line prevalence of ischemic heart disease, a higher
percentage of current smokers, and a higher rate of
self-reported lipid-lowering and antiplatelet drug use.
We adjusted for these differences in the analysis. None-
theless, better definition of cardiovascular risk, such as
knowledge of actual cholesterol levels, may have atten-
uated the observed protection in our responder group.
Although most traditional cardiovascular risk fac-
tors were captured, exercise was not measured in the
present study. Responders would be better able to
exercise than nonresponders, lowering their cardiovas-
cular risk. However, such a difference would only be
apparent following their response to treatment and is
not likely to have a large bearing on MI rates within this
short followup period.
Anti-TNF–treated patients were categorized ac-
cording to the change in DAS28 score from baseline to
6 months. These data were missing at 1 or both time
points in 1,153 patients (15%), and we therefore
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MI rate in the patients without a categorized response
was 7.7 events per 1,000 person-years. This rate is
approximately halfway between the observed rates in the
responder and nonresponder groups, suggesting that
these data may be missing at random.
The BSRBR has a number of strengths. The size
of the cohort far exceeds that of any anti-TNF clinical
trial. The aim is to recruit all RA patients in the UK
treated with these agents and thus represent real-life
practice. It is a condition of prescribing these agents in
the UK National Health Service that the rheumatologist
register the patient with the BSRBR (22). Although we
cannot accurately assess the completeness of registra-
tion, estimates from various sources have suggested a
capture rate of 70%.
It is important to remember that the risk of MI is
increased in patients with RA independent of the treat-
ment they receive. The inclusion of a cohort of
DMARD-treated patients who had never taken biologic
agents enabled us to estimate the risk reduction attrib-
utable to anti-TNF drugs, which would not be possible
if MI rates were compared with those in the general
population. By using 3 sources of identification of MIs,
we increased the chances of identifying all adverse
events. Prior to verification, there were 20 MIs reported
in the DMARD cohort and 69 in the anti-TNF cohort.
Following collection of available clinical information, 59
(10 in the DMARD cohort and 49 in the anti-TNF
cohort) were verified according to the ESC/ACC crite-
ria. A further 21 (7 in the DMARD cohort and 14 in the
anti-TNF cohort) had either a death certificate diag-
nosis of MI or received thrombolysis. There was insuf-
ficient clinical information available on the remainder
(3 in the DMARD cohort and 6 in the anti-TNF
cohort) to allow verification. A secondary analysis in-
cluding these few nonverified MIs did not noticeably
change the results.
It is also appropriate to determine whether the
observed MI rate in the comparison group was similar to
the expected outcome, which would enhance the exter-
nal validity of the result. When compared with published
data on MI rates in the general population (35) and the
risk conferred by RA (5,36), the observed rates in the
DMARD cohort of 12.0 and 3.4 events per 1,000 person-
years for men and women, respectively, suggest that
there was no major under- or overascertainment. Our
findings are also consistent with those of a recent study
from Sweden (18), which examined the effect of anti-
TNF therapy on all cardiovascular events combined
and showed a nonsignificant decrease in the incidence of
first-time severe cardiovascular events. Low numbers of
events (n  13) and a short followup time (656 person-
years) in the anti-TNF cohort in that study precluded
further analysis (18).
This study showed no protective effect against MI
in RA patients treated with anti-TNF therapy com-
pared with patients treated with traditional DMARDs,
after adjustment for baseline risk. However, the suppres-
sion of joint disease with anti-TNF therapy in RA
patients may be associated with an early reduced risk of
MI. This finding supports the notion that inflammation
plays a pivotal role in the pathophysiology of MI.
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members of the steering committee, who decide whether they
should be passed on to the authors. All publications are also
2910 DIXON ET ALreviewed by the BSR, but the material presented and the views
expressed in all publications from the BSRBR are those of the
authors and do not necessarily represent the views of the BSR.
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APPENDIX A: BSRBR CONTROL CENTRE
CONSORTIUM
The BSRBR Control Centre Consortium consists of the
following institutions (all in the UK): Antrim Area Hospital, Antrim
(Nicola Maiden); Cannock Chase Hospital, Cannock Chase (Tom
Price); Christchurch Hospital, Christchurch (Neil Hopkinson);
Derbyshire Royal Infirmary, Derby (Sheila O’Reilly); Dewsbury and
District Hospital, Dewsbury (Lesley Hordon); Freeman Hospital,
Newcastle-upon-Tyne (Ian Griffiths); Gartnavel General Hospital,
Glasgow (Duncan Porter); Glasgow Royal Infirmary, Glasgow
(Hilary Capell); Haywood Hospital, Stoke-on-Trent (Andy Hassell);
Hope Hospital, Salford (Romela Benitha); King’s College Hospital,
London (Ernest Choy); Kings Mill Centre, Sutton-In-Ashfield (David
Walsh); Leeds General Infirmary, Leeds (Paul Emery); Macclesfield
District General Hospital, Macclesfield (Susan Knight); Manchester
Royal Infirmary, Manchester (Ian Bruce); Musgrave Park Hospital,
Belfast (Allister Taggart); Norfolk and Norwich University Hospital,
Norwich (David Scott); Poole General Hospital, Poole (Paul Thomp-
son); Queen Alexandra Hospital, Portsmouth (Fiona McCrae); Royal
Glamorgan Hospital, Glamorgan (Rhian Goodfellow); Russells Hall
Hospital, Dudley (George Kitas); Selly Oak Hospital, Selly Oak
(Ronald Jubb); St. Helens Hospital, St. Helens (Rikki Abernethy);
and Withington Hospital, Manchester (Paul Sanders).
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